Interactions between antiepileptics and second-generation antipsychotics

被引:68
|
作者
de Leon, Jose [1 ,3 ]
Santoro, Vincenza [2 ]
D'Arrigo, Concetta [2 ]
Spina, Edoardo [2 ]
机构
[1] Univ Kentucky, Mental Hlth Res Ctr, Eastern State Hosp, Lexington, KY 40508 USA
[2] Univ Messina, Dept Clin & Expt Med & Pharmacol, Pharmacol Sect, Messina, Italy
[3] Univ Granada, Inst Neurosci Psychiat & Neurosci Res Grp CTS 549, Granada, Spain
关键词
amisulpride; anticonvulsants; antipsychotics; aripiprazole; asenapine; bipolar disorder; carbamazepine; clozapine; drug interactions; eslicarbazepine; ethosuximide; felbamate; gabapentin; iloperidone; lacosamide; lamotrigine; levetiracetam; lurasidone; olanzapine; oxcarbazepine; paliperidone; pharmacokinetics; phenobarbital; phenytoin; pregabalin; primidone; quetiapine; retigabine; risperidone; rufinamide; stiripentol; tiagabine; topiramate; valproate; vigabatrin; ziprasidone; zonisamide; STEADY-STATE PHARMACOKINETICS; DRUG-MONITORING SERVICE; PLASMA CLOZAPINE CONCENTRATIONS; RANDOMIZED CONTROLLED-TRIAL; OLANZAPINE SERUM CONCENTRATIONS; MAJOR DEPRESSIVE DISORDER; PREGNANE-X RECEPTOR; BIPOLAR I DISORDER; OF-THE-LITERATURE; VALPROIC ACID;
D O I
10.1517/17425255.2012.660918
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Pharmacokinetic and pharmacodynamic drug interactions (DIs) can occur between antiepileptics (AEDs) and second-generation antipsychotics (SGAPs). Some AED and SGAP pharmacodynamic mechanisms are poorly understood. AED--SGAP combinations are used for treating comorbid illnesses or increasing efficacy, particularly in bipolar disorder. Areas covered: This article provides a comprehensive review of the interactions between antiepileptics and second-generation antipsychotics. The authors cover pharmacokinetic AED--SGAP DI studies, the newest drug pharmacokinetics in addition to the limited pharmacodynamic DI studies. Expert opinion: Dosing correction factors and measuring SGAP levels can help to compensate for the inductive properties of carbamazepine, phenytoin, phenobarbital and primidone. Further studies are needed to establish the clinical relevance of combining: i) AED strong inducers with amisulpride, asenapine, iloperidone, lurasidone and paliperidone; ii) valproate with aripiprazole, asenapine, clozapine and olanzapine; iii) high doses of oxcarbazepine (1500 mg/day) or topiramate (>= 400 mg/day) with aripiprazole, lurasidone, quetiapine, risperidone, asenapine and olanzapine. Two pharmacodynamic DIs are beneficial: i) valproate-SGAP combinations may have additive effects in bipolar disorder, ii) combining topiramate or zonisamide with SGAPs may decrease weight gain. Three pharmacodynamic DIs contributing to decreased safety are common: sedation, weight gain and swallowing disturbances. A few AED--SGAP combinations may increase risk for osteoporosis or nausea. Three potentially lethal but rare pharmacodynamic DIs include pancreatitis, agranulocytosis/leukopenia and heat stroke. The authors believe that collaboration is needed from drug agencies and pharmaceutical companies, the clinicians using these combinations, researchers with expertise in meta-analyses, grant agencies, pharmacoepidemiologists and DI pharmacologists for future progression in this field.
引用
收藏
页码:311 / 334
页数:24
相关论文
共 50 条
  • [21] Commentary: Aripiprazole: The Second Wave of the Second-generation Antipsychotics
    Kahn, David A.
    JOURNAL OF PSYCHIATRIC PRACTICE, 2019, 25 (02) : 146 - 147
  • [22] Differences between men and women in side effects of second-generation antipsychotics
    Aichhorn, W.
    Whitworth, A. B.
    Weiss, E. M.
    Hinterhuber, H.
    Marksteiner, J.
    NERVENARZT, 2007, 78 (01): : 45 - +
  • [23] Second-generation antipsychotics and bone turnover in schizophrenia
    Okita, Kyoji
    Kanahara, Nobuhisa
    Nishimura, Motoi
    Yoshida, Toshihiko
    Yasui-Furukori, Norio
    Niitsu, Tomihisa
    Yoshida, Taisuke
    Ishikawa, Masatomo
    Kimura, Hiroshi
    Nomura, Fumio
    Iyo, Masaomi
    SCHIZOPHRENIA RESEARCH, 2014, 157 (1-3) : 137 - 141
  • [24] Second-generation antipsychotics for obsessive compulsive disorder
    Komossa, Katja
    Depping, Anna M.
    Meyer, Magdalena
    Kissling, Werner
    Leucht, Stefan
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (12):
  • [26] The ups and downs of dosing second-generation antipsychotics
    Citrome, Leslie
    Jaffe, Ari
    Levine, Jerome
    PSYCHIATRIC SERVICES, 2007, 58 (01) : 11 - 11
  • [28] Metabolic risk in selected second-generation antipsychotics
    Kerna, V.
    Nosalova, G.
    Ondrejka, I
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2010, 111 (12): : 640 - 643
  • [30] Second-generation antipsychotics and quality of life in schizophrenia
    Leucht, Stefan
    Davis, John M.
    LANCET PSYCHIATRY, 2016, 3 (08): : 694 - 695